1. Артемьев Д.В., Обухова А.В. Современные подходы к лечению ранних стадий болезни Паркинсона. Consilium Medicum 2008; 10 (7): 89–92.
2. Левин О.С. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. Леч. нервн. бол. 2003; 4 (1): 14–7.
3. Нодель М.Р., Артемьев Д.В., Яхно Н.Н.. Эффективность дофаминового агониста мирапекса при болезни Паркинсона. Неврол. журн. 1999; 6 (4): 45–9.
4. Федорова Н.В., Кулуа Т.К. Опыт применения прамипексола в лечении болезни Паркинсона. Consilium Medicum 2007; 9 (2): 103–7.
5. Федорова Н.В., Смоленцева И.Г., Левин О.С. Применение агонистов дофаминовых рецепторов при болезни Паркинсона. Рус. мед. журн. 2000; 8 (15): 643–7.
6. Chaudhuri KR, Healy DG, Schapira AH. National Institute for Clinical Exellene. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235–45.
7. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ. Comparison of pramipexole, fluoxetini, and placebo in patients with major depression. Depress. Anxiety 2000; 11: 58–65.
8. Fhan S, Oakes O, Shoulson I et al. Levodopa and progression of Parkinson's disease. N. Engl J Med 2004; 351: 2498–508.
9. Goetz C.G. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990; 40 (Suppl. 3): 50–4.
10. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? Neurology 1999; 52: 1227–9.
11. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry 1999; 156: 798.
12. Hauzer R, Reider C, Stacey M et al. Acute versus gradual pramipexole to ropinirile switch. Mov Disord 2000; 15 (Suppl. 3): 133.
13. Holloway RG, Shoulson I, Kieburts K et al. Pramipexole vs. levodopa as initial treatment for Parkinson's disease – a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044–53.
14. Jenner P. The MPTP-treated primate as a model of motor complications. Neurology 2003; 61 (Suppl. 3): 4–11.
15. Junghanns S, Glockler T, Reichmann H. Switching and combing of dopamine agonists. J Neurol 2004; 251 (Suppl. 6): 19–23.
16. Junghanns S., Glockler T., Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004; 251 (Suppl. 6): 19–23.
17. King DF, Cooper JM, Schapira AH. Pramipexole protects against MPP+toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. Neurology 2001; 56: 377–88.
18. Lang A.E. Are the new dopamine agonists better than the old ones? 6th International congress of Parkinson's disease and movement disorders Barcelona, Spain, 2000.
19. Lemke MR, Brecht HM, Koester J еt al. Anhgedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neurops Clin Neurosc 2005; 17: 214–20.
20. Lev N, Dialdetti R, Melamed E. Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists vs. levodopa. J Neurol 2007; 254 (suppl. 5): 19–26.
21. Linazasoro G. Conversion from dopamine agonists to pramipexole. J Neurol 2004; 251: 335–9.
22. Molho ES, Factor SA, Weiner WJ et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 1995; 45 (Suppl): 225–30.
23. Navan P, Findley LJ, Pearce RG et al. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide. Eur J Neurol 2005; 12 (1): 1–8.
24. Noyes K, Dick A, Holloway RG. and the Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized clinical-economic trail. Med Decis Making 2004; 24: 472–85.
25. Oertel WH. Pergolide vs Levodopa (PELMOPET). Mov Disord 2000; 15 (Suppl. 3): 86.
26. Oertel WH, Wolters E, Sampaio C еt al. Pergolide vs. levodopa monotherapy in early Parkinson's disease patients: PELMOPET study. Mov Disord 2006; 21: 343–53.
27. Olanov CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson's disease:current controversies. Mov Disord 2004; 19: 997–1005.
28. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease:A randomized controlled trial. JAMA 2000; 284: 1931–8.
29. Рarkinson Study Group. A randomized controlled trial comparing Pramipexole with Levodopa in early Parkinson's disease: design and methods of the CALM-PD study. J Clin Neuropharmakol 2000; 23 (1): 34–44.
30. Pogarell O, Gasser T, Hilten J et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomized, double-blind study, placebo controlled multicenter study. J Neurol Neurosurg Psychiatry 2002; 72: 713–20.
31. Pogarell O, Gasser T, van Hilten J et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomized, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72: 713–20.
32. Rajput AH. Adverse effects of ergot-derivative dopamine agonists. Eds: C.Olanow, J.Obeso. Dopamine agonists in early Parkinson's disease. Kent, – UK: Wells Medical 1997; 209–16.
33. Rascol O, Brooks DJ, De Deyn P et al. Five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl Med 2000; 342: 1484–91.
34. Rascol O, Rayoux P, Ferreira J et al. The management of patients with early Parkinson's didease. Parkinonism Relat Disord 2002; 9: 61–7.
35. Reichmann H, Odin P, Brecht HM et al. Changing dopamine agonist treatment in Parkinson's disease: experience with switching to pramipexole. J Neural Transm 2006; 71 (Suppl.): 17–25.
36. Samii A, Nutt JG, Ranson BR. Parkinson's disease. Lancet 2004; 363: 1783–94.
37. Schapira AH. Neuroprotection and dopamine agonists. Neurology; 58 (Suppl. 1): 9–18.
38. Schapira AH, Hsu HH, Scrine K et al. PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. Mov Disor 2008; 23 (Supp. 1): 194.
39. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson' disease: a need for reappraisal? Ann Neurol 2006; 59: 562–4.
40. Stocchi F, Berardelli A, Vacca L et al. Combination of two different dopamine agonists in the management of Parkinson's disease. Neurol Sci 2002; 23 (Suppl. 2): 115–6.
41. Takahashi H, Nogawa S, Tachibana J et al. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching. J Int Med Res 2008; 36 (1): 106–14.
42. Tatton WG, Ju WYH, Wadia J et al. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. Eds. C.Olanov, P.Jenner, M.Youim. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press 1996; 202–20.
43. Thomas A, Bonanni L, Di Lorio A et al. End-of-dose deterioration in non ergolinic dopamine agonist monoterapy of Parkinson's disease. J Neurol 2006; 253: 1633–9.
44. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. Drugs 1996; 5: 369–88.
45. Wolters EC, Tissingh G, Bergmans PLM et al. Dopamine agonists in Parkinson's disease. Neurology. 1995; 45 (Suppl. 3): 28–34.

Н.В.Федорова